EP 2964673 A4 20170222 - ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING
Title (en)
ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING
Title (de)
ANTIKÖRPER GEGEN HGF UND ZUSAMMENSETZUNGEN DAMIT
Title (fr)
ANTICORPS DIRIGÉS CONTRE HGF ET COMPOSITIONS LES CONTENANT
Publication
Application
Priority
- US 201361781643 P 20130314
- US 201361782868 P 20130314
- US 2014029163 W 20140314
Abstract (en)
[origin: WO2014153117A2] The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.
IPC 8 full level
C07K 16/22 (2006.01)
CPC (source: EP)
A61K 45/06 (2013.01); A61P 1/04 (2017.12); A61P 1/16 (2017.12); A61P 1/18 (2017.12); A61P 5/14 (2017.12); A61P 11/00 (2017.12); A61P 13/08 (2017.12); A61P 13/10 (2017.12); A61P 13/12 (2017.12); A61P 15/00 (2017.12); A61P 17/00 (2017.12); A61P 25/00 (2017.12); A61P 25/28 (2017.12); A61P 27/02 (2017.12); A61P 33/06 (2017.12); A61P 35/00 (2017.12); A61P 35/02 (2017.12); A61P 43/00 (2017.12); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); Y02A 50/30 (2017.12)
Citation (search report)
- [I] WO 2007143090 A2 20071213 - AVEO PHARMACEUTICALS INC [US], et al
- [I] WO 2005107800 A1 20051117 - KIM KYUNG JIN [US], et al
- [I] WO 2005017107 A2 20050224 - AMGEN INC [US], et al
- [A] WO 2007143098 A2 20071213 - AVEO PHARMACEUTICALS INC [US], et al
- [I] P. Y. WEN ET AL: "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma", NEURO-ONCOLOGY, vol. 13, no. 4, 1 April 2011 (2011-04-01), pages 437 - 446, XP055084095, ISSN: 1522-8517, DOI: 10.1093/neuonc/noq198
- [I] T. L. BURGESS ET AL: "Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 2, 1 February 2010 (2010-02-01), US, pages 400 - 409, XP055308025, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0824
- See references of WO 2014153117A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2014153117 A2 20140925; WO 2014153117 A3 20150108; WO 2014153117 A9 20141127; CA 2904743 A1 20140925; CN 105246915 A 20160113; EP 2964673 A2 20160113; EP 2964673 A4 20170222; JP 2016516052 A 20160602; KR 20150140685 A 20151216; TW 201438737 A 20141016; TW 201444868 A 20141201; WO 2014153166 A2 20140925; WO 2014153166 A3 20141204
DOCDB simple family (application)
US 2014029163 W 20140314; CA 2904743 A 20140314; CN 201480026978 A 20140314; EP 14767985 A 20140314; JP 2016503002 A 20140314; KR 20157029279 A 20140314; TW 103109575 A 20140314; TW 103109578 A 20140314; US 2014029383 W 20140314